Sarepta Therapeutics (SRPT)

Executive Summary

Sarepta Therapeutics is a biotechnology leader in precision genetic medicines for rare neuromuscular diseases, with a strong commercial portfolio including EXONDYS 51, VYONDYS 53, and the gene therapy Elevidys for Duchenne muscular dystrophy (DMD). The company's pipeline extends to next-generation exon-skipping therapies, limb-girdle muscular dystrophy (LGMD) programs, and CNS disorders. Key near-term catalysts include regulatory decisions for Elevidys label expansion into younger and non-ambulatory patients, Phase 3 data for eteplirsen in older DMD patients, and progress on SRP-5051, a potentially more potent exon 51 skipping agent. With a robust approved product base and a pipeline addressing high unmet need, Sarepta is well-positioned for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Elevidys label expansion decision to include younger DMD patients (under 4 years) or non-ambulatory patients80% success
• Q4 2026Phase 3 topline results for eteplirsen in DMD patients amenable to exon 51 skipping (MISSION trial)70% success
• TBDSRP-5051 Phase 2/3 data readout for DMD patients amenable to exon 51 skipping60% success